Missouri Cannabis Industry Set for Financial Windfall as Trump Executive Order Reclassifies Marijuana
ST. LOUIS, MO (STL.News) The landscape of the American cannabis industry underwent a seismic shift this week as President Trump signed a landmark executive order titled “Increasing Medical Marijuana and Cannabidiol Research.” For the thousands of business owners, employees, and patients within Missouri’s thriving cannabis market, the order represents much more than a policy change—it marks the end of a “punitive tax era” that has stifled the industry since its inception.
By directing the Department of Justice and Attorney General Pam Bondi to fast-track the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, the federal government is effectively acknowledging the medical utility of the plant. However, for Missouri’s dispensaries, cultivators, and manufacturers, the most immediate and profound impact is not medical, but mathematical.
The Death of Section 280E: A Game Changer for the Show-Me State
For years, the Missouri cannabis industry has operated under the shadow of Internal Revenue Code Section 280E. This Reagan-era tax provision was designed to prevent drug kingpins from deducting business expenses from their taxes. Because marijuana was classified as a Schedule I substance—the same category as heroin—legal, state-licensed businesses were treated as “drug traffickers” in the eyes of the IRS.
Under 280E, Missouri cannabis companies could only deduct their Cost of Goods Sold (COGS). Essential business expenses—such as rent, electricity, security, employee health insurance, marketing, and payroll—were non-deductible. This resulted in “phantom profits,” in which businesses were forced to pay federal taxes on their gross income rather than their net income. It was not uncommon for a Missouri dispensary to face an effective federal tax rate of 70% to 90%.
The transition to Schedule III removes marijuana from the reach of Section 280E entirely. Once finalized, Missouri cannabis businesses will be treated like any other legitimate retail or agricultural enterprise. They will be able to claim standard business deductions, potentially saving the state’s industry hundreds of millions of dollars in annual federal tax payments. This massive injection of liquidity is expected to fuel a new wave of hiring, infrastructure investment, and local expansion across St. Louis, Kansas City, and Springfield.
Missouri’s Unique Regulatory Environment
Missouri is uniquely positioned to capitalize on this federal shift. Unlike some states that strictly mirror federal tax policy, Missouri’s legislature had the foresight to “decouple” from Section 280E at the state level in 2022. This means that Missouri operators were already allowed to deduct business expenses on their state income tax returns.
However, the state-level relief was a drop in the bucket compared to the federal burden. With the new executive order, the dual-bookkeeping nightmare that has plagued the industry is coming to an end. Operators will no longer need to maintain complex accounting structures to satisfy two vastly different tax authorities. Aligning federal and state tax rules will significantly reduce the compliance costs for Missouri’s small businesses.
The “Oz” Factor: Medicare and Medical Access
The executive order isn’t just about taxes; it’s about integration into the broader healthcare system. President Trump has tasked CMS Administrator Dr. Mehmet Oz with spearheading a pilot program that could change the way Missouri seniors access relief.
Beginning as early as April 2026, the administration plans to launch models allowing Medicare and Medicaid beneficiaries to access medically prescribed CBD and hemp-derived products with federal support. The order suggests a $500 annual cap for such treatments, prioritizing non-addictive alternatives to opioids for chronic pain management. For Missouri’s aging population, this could provide a safer, federally subsidized path to wellness that was previously unavailable due to federal restrictions.
Research and the “Bureaucratic Minefield“
For the scientific community at institutions such as the University of Missouri and Washington University in St. Louis, the reclassification to Schedule III is a long-awaited breakthrough. Schedule I status required researchers to jump through extraordinary hoops, including high-level DEA security clearances and restricted access to federally approved “research grade” cannabis that often didn’t reflect the products actually sold in Missouri dispensaries.
The executive order mandates that federal agencies strip away these “bureaucratic minefields.” By easing these restrictions, the administration is clearing the way for Missouri-based clinical trials to study the efficacy of cannabis for conditions ranging from PTSD to pediatric epilepsy. This data-driven approach is a cornerstone of the administration’s strategy to treat cannabis as a legitimate component of the American pharmaceutical and wellness landscape.
A Measured Approach: Regulation Over Legalization
It is critical to note that this executive order is not federal legalization. Marijuana remains a controlled substance, and the “patchwork” of state laws remains the law of the land.
The order also takes a firm stance on the unregulated “gray market.” President Trump has directed the White House to work with Congress to crack down on “intoxicating hemp products”—specifically Delta-8 and other synthetically derived cannabinoids—that have appeared in gas stations and convenience stores across Missouri. The goal is to steer consumers toward the highly regulated, tested, and taxed “full-spectrum” products available at licensed dispensaries, ensuring public safety and product consistency.
Economic Implications for St. Louis and Beyond
Missouri has already proven itself a powerhouse in the cannabis sector, with monthly sales figures frequently rivaling or surpassing those of more established markets like Colorado and Illinois. The “reclassification windfall” is expected to have a multiplier effect on the local economy.
As federal tax liabilities drop, Missouri companies will have the capital to:
- Lower Consumer Prices: Increased margins may allow dispensaries to lower prices, making legal products more competitive against the illicit market.
- Increase Wages: The cannabis industry is already a major employer in the state; tax relief provides the “breathing room” to offer more competitive salaries and benefits.
- Community Investment: Under the state’s existing social equity and micro-licensing programs, the influx of capital could help smaller, minority-owned businesses gain a stronger foothold in the market.
Looking Ahead
As Attorney General Pam Bondi moves to finalize the rulemaking process, the Missouri Department of Revenue is expected to issue updated guidance for the 2025 tax year. The industry is currently awaiting word on whether the IRS will allow these tax changes to be applied retroactively, which could trigger a wave of refund requests from businesses that have already paid estimated taxes under the 280E regime.
While critics of the move argue that it does not go far enough toward full descheduling, the consensus within the Missouri business community is one of overwhelming relief. The “Show-Me State” is now poised to show the rest of the country how a mature, regulated cannabis market can thrive when the federal government finally steps out of the way of local progress.
© 2025 STL.News/St. Louis Media, LLC. All Rights Reserved. Content may not be republished or redistributed without express written approval. Portions or all of our content may have been created with the assistance of AI technologies, like Gemini or ChatGPT, and are reviewed by our human editorial team. For the latest news, head to STL.News.
